U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H13Cl2N3O2
Molecular Weight 434.274
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of AGK-2

SMILES

ClC1=CC=C(Cl)C(=C1)C2=CC=C(O2)\C=C(/C#N)C(=O)NC3=C4C=CC=NC4=CC=C3

InChI

InChIKey=SVENPFFEMUOOGK-SDNWHVSQSA-N
InChI=1S/C23H13Cl2N3O2/c24-15-6-8-19(25)18(12-15)22-9-7-16(30-22)11-14(13-26)23(29)28-21-5-1-4-20-17(21)3-2-10-27-20/h1-12H,(H,28,29)/b14-11+

HIDE SMILES / InChI

Molecular Formula C23H13Cl2N3O2
Molecular Weight 434.274
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

The histone deacetylases (HDACs), Sirtuin 1 (Sirt1) and Sirt2, play crucial roles in many biological processes, including cell proliferation, differentiation, and apoptosis. AGK2 is a cell-permeable, selective inhibitor of sirtuin 2 (SIRT2), which as was shown, prevented cellular α-tubulin deacetylation in HeLa cells in a dose-dependent manner and with little cytotoxic effect. AGK2 can be a useful tool for studying the roles of SIRT2 in neurodegeneration and aging, as well as cell cycle progression and tumorigenesis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q8IXJ6|||U5TP13
Gene ID: 22933.0
Gene Symbol: SIRT2
Target Organism: Homo sapiens (Human)
3.5 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
The Sir2 family of protein deacetylases.
2004
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.
2007 Jul 27

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
It was examined insoluble, polymerized microtubules and soluble alpha-tubulin after treatment of HeLa cells with either AGK2 or AGK3, a less potent structural analog of AGK2, for 3 hours. A dose dependent increase in acetylated tubulin was observed in both fractions of AGK2 treated cells relative to untreated or AGK3-treated cells. Thus, AGK2 could enter cells and act on endogenous SIRT2 in its native environment. AGK2 (5, 10, 20, 30, 40, 50 Um) treatment results in a dose-dependent increase in acetylation of soluble tubulin monomers (S) and polymerized microtubules (P) in fractionated HeLa cell extracts. The effect of the less potent SIRT2 inhibitor AGK3 was shown for comparison.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:00:27 GMT 2023
Edited
by admin
on Sat Dec 16 09:00:27 GMT 2023
Record UNII
DDF0L8606A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AGK-2
Common Name English
2-PROPENAMIDE, 2-CYANO-3-(5-(2,5-DICHLOROPHENYL)-2-FURANYL)-N-5-QUINOLINYL-
Systematic Name English
Code System Code Type Description
PUBCHEM
2130404
Created by admin on Sat Dec 16 09:00:27 GMT 2023 , Edited by admin on Sat Dec 16 09:00:27 GMT 2023
PRIMARY
EPA CompTox
DTXSID80184559
Created by admin on Sat Dec 16 09:00:27 GMT 2023 , Edited by admin on Sat Dec 16 09:00:27 GMT 2023
PRIMARY
FDA UNII
DDF0L8606A
Created by admin on Sat Dec 16 09:00:27 GMT 2023 , Edited by admin on Sat Dec 16 09:00:27 GMT 2023
PRIMARY
CAS
304896-28-4
Created by admin on Sat Dec 16 09:00:27 GMT 2023 , Edited by admin on Sat Dec 16 09:00:27 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY